[
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In this review, our aim is to describe the advantages and disadvantages of current and developing models for brain tumors with the highest incidence (meningiomas) or morbidity and mortality (gliomas, medulloblastoma, and ependymomas) in adulthood and childhood that could lead to new therapeutic strategies (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On the other hand, GEMMs have also serious and important pitfalls such as the lack of intra-tumor heterogeneity and the diversity of blood–brain barrier (BBB) in the mouse brain compared to the human one (Aday et al., 2016), thus affecting the treatment delivery.Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Recently, injection of engineered NSCs (Nf1 and Pten KO + EGFRvIII overexpression) into immunocompetent syngeneic mouse strain has been used to propose an epigenetic-driven mechanism exploited by GBM stem cells to evade immune system (Gangoso et al., 2021).Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Xenograft models can also be obtained by primary tumors (Sasaki et al., 2001; Joo et al., 2013; Kerstetter-Fogle et al., 2020) (Figure 2A and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Genetically Engineered Mouse Model\nThe genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The genetically engineered mouse model (GEMM) represents one of the most reliable in vivo models to study whether specific genetic alterations are responsible for tumor initiation and progression (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drosophila melanogaster\nDrosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Drosophila melanogaster is a powerful genetic model that can be successfully used to study cancer biology (Figure 2C and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Thanks to its short embryonic developmental time, small size, and its transparency, coupled with conservation of genetic mechanisms underlying biological processes and the possibility to transplant human cells; it represents an important model for gliomas studies (Figure 2D and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "There are two main cellular sources for deriving tumor organoids: the patient tumor biopsies (Figure 2E and Table 1) and pluripotent stem cells derived brain organoids (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the same in vivo approach of genes in human gliomas (i.e., HRASG12V and TP53–/–; cMYC overexpression; EGFRvIII and EGFR overexpression and CDKN2A–/–; NF1–/– and PTEN–/– and TP53–/–), cerebral organoids derived from human-induced pluripotent stem cells (hiPSCs) were modified in order to induce neoplastic organoids (Bian et al., 2018; Ogawa et al., 2018) (Figure 2F and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Similarly, Linkous et al. (2019) described a model of co-culturing GBM-derived GSCs with brain organoids, called GLICO (Figure 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "For this reason, Gibson and collaborators generated Blbp-Cre+; Ctnnb1+/lox(ex3); Tp53flx/flx mice, characterized by a dominant mutation of the beta-catenin gene and loss of the tumor suppressor Tp53 in Blbp+ cells, which are Olig3+ progenitor cells in the LRL and progenitor cell populations across the hindbrain (including the cerebellar ventricular zone) (Gibson et al., 2010) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Indeed, granule lineage identity is a prerequisite for the SHH MB onset, as it has been demonstrated by the conditional Ptch1 knockout in unipotent (Math1+) CGNPs (Schüller et al., 2008; Yang et al., 2008) and through the deregulation of different effectors of the SHH pathway, such as Smoothened and Sufu (Lee et al., 2007; Dey et al., 2012) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Either overexpressing oncogenes with the PiggyBac transposon system or by CRISPR/Cas9-mediated deletion of tumor suppressor genes, we found that Gfi1 + c-MYC and Otx2 + c-MYC genes overexpressions were able to mimic the histological and transcriptional profile of human Group 3 MB (Ballabio et al., 2020) (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, in utero electroporation in the fourth ventricle of E13.5 mouse embryos of the active form of SRC, together with a dominant negative form of TP53, leads to Group 4 MB formation (Figure 2B and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These Group 3 MB organoid models more closely mimic the histological, transcriptional, and DNA methylation profile of human Group 3 MB (Ballabio et al., 2020, 2021) (Figure 2B and Table 1), suggesting that they could be a more suitable platform for high-throughput drug testing and development of personalized therapies (Qian et al., 2019).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Histologically, ependymomas are classified into four groups: subependymoma (WHO Grade I), myxopapillary ependymoma and classic ependymoma (WHO Grade II), and anaplastic ependymoma (WHO Grade III), of which classic and anaplastic ependymoma are the most common subtypes in children (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "All the brain tumor models developed so far have shown some pitfalls in the correct modeling of the disease and the human translation of the findings (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]